Marker Therapeutics (MRKR) Operating Expenses (2010 - 2026)

For the trailing twelve months through Jun 30, 2026, Operating Expenses at Marker Therapeutics was $13.05 million, down 36.4% year-over-year; for FY2025, it came in at $16.44 million, down 7.2% from FY2024.

• Annual Operating Expenses has declined for four consecutive years, with a five-year compound annual growth rate of -10.9% (FY2020 to FY2025).
• In prior years, Marker Therapeutics' Operating Expenses was $17.71 million in FY2024 (-1.0%), $17.89 million in FY2023 (-23.2%), $23.3 million in FY2022 (-42.8%) and $40.72 million in FY2021 (+38.7%).
• The Q2 2026 figure stands as the lowest quarterly Operating Expenses since Q2 2017.
• On a year-over-year basis, Operating Expenses has declined in each of the last four quarters, with growth averaging 2.0% over the last eight quarters.
• The strongest year-over-year quarter for Operating Expenses in the past five years was Q4 2024, with growth of 53.0%; the weakest was Q4 2022, with a decline of 65.5%.
• According to Business Quant data, Operating Expenses for the three prior quarters was $4.07 million (Q1 2026), $2.99 million (Q4 2025) and $3.37 million (Q3 2025).